Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β

Journal of Interferon and Cytokine Research

Volumn 33, Issue 11, 2013, Pages 660-671

  Wadhwa, Meenu ^a   Subramanyam, Meena ^b   Goelz, Susan ^b   Goyal, Jaya ^b   Jethwa, Vijay ^b   Jones, Wendy ^b   Files, James G ^c   Kramer, Daniel ^d   Bird, Chris ^a   Dilger, Paula ^a   Tovey, Michael ^e   Lallemand, Christophe ^e   Thorpe, Robin ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b BIOGEN   (United States)

^c BAYER AG   (Germany)

^d MERCK KGAA   (Germany)

^e Ecole Normale Superieure de Cachan   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; BETA INTERFERON; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN;

ANTIBODY TITER; ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; IMMUNOGENICITY; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MARKETING; PRIORITY JOURNAL; PROTEIN DETERMINATION; STANDARDIZATION; VALIDATION STUDY; BLOOD; IMMUNOLOGY; MULTIPLE SCLEROSIS; STANDARD;

ORTHOMYXOVIRIDAE;

ANTIBODIES, NEUTRALIZING; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; MYXOVIRUS RESISTANCE PROTEINS; REFERENCE STANDARDS;

EID: 84881550245     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0079     Document Type: Article

References (49)

1. Aarskog N, Mary T, Myhr K, Vedeler C. 2009. Antibodies against interferon-beta in multiple sclerosis. J Neuroimmunol 212:148-150.
2. Bertolotto A. 2009. Implications of neutralising antibodies on therapeutic efficacy. J Neurol Sci 277 Suppl 1:S29-S32.
3. Bertolotto A, Deisenhammer F, Gallo P, So lberg Srensen P. 2004. Immunogenicity of interferon beta: differences among products. J Neurol 251 Suppl 2:II15-II24.
4. Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Lindberg RL, Bottero R, Di Sapio A, Giordana MT. 2003. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60:634-639.
5. Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, and others. 2007. Development and validation of a real time PCRbased bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods 321:19-31.
6. Clerico M, Contessa G, Durelli L. 2007. Interferon-beta1-A for the treatment of multiple sclerosis. Expert Opin Biol Ther 7: 535-542.
7. Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L. 2012. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 11(1):33-41.
8. Deisenhammer F. 2009. Neutralizing antibodies to interferonbeta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 23:379-396.
9. Dhib-Jalbut S, Marks S. 2010. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 74 Suppl 1:S17-S24.
10. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M; Independent Comparison of Interferon (INCOMIN) Trial Study Group. 2002. Every-otherday interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359(9316):1453-1460.
11. European Medicines Agency (EMA). 2007. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Available at www.emea.europa.eu/pdfs/ human/biosimilar/1432706en.pdf
12. European Medicines Agency (EMA). 2008. Beta-interferons and neutralising antibodies (in multiple sclerosis), EMEA/ CHMP/BWP/580136/2007. Available at www.ema.europa .eu/docs/en-GB/document-library/Report/2009/11/ WC500015395.pdf
13. Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G. 2011. Incorporation of an interferon-b neutralizing antibody assay into routine clinical practice. Mult Scler 17(11):1333-1340.
14. Farrell RA, Giovannoni G. 2010. Current and future role of interferon beta in the therapy of multiple sclerosis. J Interferon Cytokine Res 30(10):715-726.
15. Files JG, Gray JL, Do LT, Foley WP, Gabe JD, Nestaas E, Pungor E, Jr. 1998. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 18(12):1019-1024.
16. Files JG, Hargrove D, Delute L, Cantillon M. 2007. Measured neutralizing titres of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay. J Interferon Cytokine Res 27(8):637-642.
17. Francis GS, Rice GP, Alsop JC; PRISMS Study Group. 2005. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65(1):48-55.
18. Giovannoni G. 2012. The REFLEX study: a missed opportunity? Lancet Neurol 11(1):22-24.
19. Gneiss C, Koudouovoh-Tripp PM, Ropele S, Gotwald T, Ehling R, Lutterotti A, Aichner F, Ladurner G, Eggers C, Schautzer F, Ku nz B, Millonig A, Aspeck E, Reindl M, Berger T, Fazekas F, Deisenhammer F. 2009. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study (ASS). Mult Scler 15:1481-1488.
20. Goodin DS. 2005. Treatment of multiple sclerosis with human beta interferon. Int MS J 12:96-108.
21. Goodin DS, Hartung HP, OConnor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C; BEYOND Study Group. 2012. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler 18(2):181-195.
22. Goodin DS, Hurwitz B, Noronha A. 2007. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 35(2):173-187.
23. Grossberg SE, Kawade Y, Kohase M, Klein JP. 2001a. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 21:743-755.
24. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. 2001b. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon and Cytokine Res 21:729-742.
25. Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, and others. 2007. Neutralizing antibodies to interferon beta in multiple sclerosis: expert panel report. J Neurol 254:827-837.
26. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, and others. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294.
27. Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S. 2005.European Interferon Beta-1a IM Dose-Comparison Study Investigators. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65(1):40-47.
28. Karpusas M, Whitty A, Runkel L, Hochman P. 1998. The structure of human interferon-beta: implications for activity. Cell Mol Life Sci 54:1203-1216.
29. Kawade Y. 1986. Quantitation of neutralization of interferon by antibodies. Methods Enzymol 119:558-573.
30. Killestein J, Rudick RA, Polman CH. 2011. Oral treatment for multiple sclerosis. Lancet Neurol 10(11):1026-1034.
31. Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM. 2009. The clinical effect of neutralizing antibodies against interferon- beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Mult Scler 15:601-605.
32. Lallemand C, Meritet JF, Erickson R, Grossberg SE, Roullet E, and others 2008. Quantification of neutralizing antibodies to human type I interferons using division-Arrested frozen cells carrying an interferon-regulated reporter-gene. J Interferon Cytokine Res 28:393-404.
33. Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J. 2008. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFN beta in multiple sclerosis patients. J Immunol Methods 336:113-118.
34. Li DK, Paty DW. 1999. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebocontrolled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 46(2):197-206.
35. Lublin FD, Reingold SC. 1996. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46:907-911.
36. McKay F, Schibeci S, Heard R, Stewart G, Booth D. 2006. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australian cohort. J Immunol Methods 310:20-29.
37. Meager A, Gaines Das R. 2005. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta. J Immunol Methods 306:1-15.
38. Moore M, Meager A, Wadhwa M, Burns C. 2009. Measurement of neutralizing antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA. J Pharm Biomed Anal 49:534-539.
39. Pachner AR, Cadavid D, Wolansky L, Skurnick J. 2009. Effect of anti-IFN {beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology 73:1485-1492.
40. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Srensen PS. 2010. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 9(7):740-750.
41. PRISMS (Prevention of Relapses and Disability for Interferon beta-1a subcutaneously in Multiple Sclerosis) Study Group. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing multiple sclerosis. Lancet 352:1498-1504.
42. Pungor E, Jr., Files JG, Gabe JD, Do LT, FoleyWP, and others. 1998. A novel bioassay for the determination of neutralizing antibodies to IFNb1. J Interferon Cytokine Res 18:1025-1030.
43. Rio J, Porcel J, Tellez N, and others. 2005. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 11:306-309.
44. Rudick RA, Goelz SE. 2011. Beta-interferon for multiple sclerosis. Exp Cell Res 317(9):1301-1311.
45. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-b (IFN - b). Pharm Res 15:641-649.
46. Scagnolari C, Duda P, Bagnato F, De Vito G, Alberelli A, Lavolpe V, Girardi E, Durastanti V, Trojano M, Kappos L, Antonelli G. 2007. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J Neurol 254:597-604.
47. Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A. 2007. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 13:208-214.
48. Towbin H, Schmitz A, Jakschies D, Von Wussow P, Horisberger MA. 1992. A whole blood immunoassay for the interferoninducible human Mx protein. J Interferon Res 12(2):67-74.
49. van Beers MM, Sauerborn M, Gilli F, Hermeling S, Brinks V, Schellekens H, Jiskoot W. 2010. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. J Immunol Methods 352(1-2):32-37.